We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Reprise par OPM de l’intégralité des droits du programme OPM-201 et du portefeuille de brevets associé Confirmation de l’innocuité de la molécule chez les volontaires sains Regulatory News:...
Finalisation du rapport d’étude de l’essai de phase 1 de l’OPM-101 contrôlé par placebo en double aveugle chez 104 volontaires sains (VS) ayant reçu OPM-101 L’analyse des ECG enregistrés sur 24h...
Presentation by Professor Laurent Peyrin-Biroulet (M.D., PhD Professor of Gastroenterology at CHRU of Nancy) and Bruno Robin (PharmD, Head of OPM Clinical Development) of safety, pharmacokinetic...
OPM-101 conclut positivement sa Phase 1 volontaires sains permettant de prévoir le démarrage d'un essai clinique de Phase 1b/2a, fin 2024 début 2025 OPM-201, licenciée à Servier dans la maladie...
End of double-blind, placebo-controlled phase 1 trial with OPM-101: 104 healthy volunteers (VS) participated in this trial designed to assess the safety of OPM-101 in humans Very good safety...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.13 | -12.7450980392 | 1.02 | 1.02 | 0.73 | 4632 | 0.99217306 | DE |
4 | -0.14 | -13.5922330097 | 1.03 | 1.075 | 0.73 | 6734 | 1.03352811 | DE |
12 | -0.135 | -13.1707317073 | 1.025 | 1.38 | 0.73 | 8832 | 1.17583155 | DE |
26 | -0.145 | -14.0096618357 | 1.035 | 1.38 | 0.73 | 10160 | 1.12320636 | DE |
52 | -0.91 | -50.5555555556 | 1.8 | 2.06 | 0.73 | 10837 | 1.26891184 | DE |
156 | -0.1 | -10.101010101 | 0.99 | 2.39 | 0.73 | 10504 | 1.46483635 | DE |
260 | -0.1 | -10.101010101 | 0.99 | 2.39 | 0.73 | 10504 | 1.46483635 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions